Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
-Medical News
 Blood Safety News
 NHF and Community News
 Industry News
 Travel Advisory

 

 

 
Biotechnology Company Receives Federal Funds to Develop HIV Vaccine
 

Maxygen, Inc., a biotechnology company based in Redwood City, CA has been awarded research grants totaling $14.4 million to continue work in developing an HIV vaccine. The majority of this new funding comes from a five-year, $11.7 million award from the National Institutes of Health (NIH). These grants are part of the NIH Small Business Innovation Research and HIV Research and Development programs. The remaining funds come via contract with the U.S. Department of Defense.

 

“We are pleased to be able to advance our work in HIV vaccine discovery with government grant and contract funding. Maxygen has demonstrated the ability to improve key attributes of experimental vaccines to make them more effective against multiple pathogen strains in laboratory studies. We hope to translate our past success in the laboratory into a much needed broadly-protective HIV vaccine,” said Maxygen CEO Russell Howard.

 

Source: Maxygen news release dated October 20, 2005 and BIOWORLD Today, October 24, 2005

 

This section of our Web site is sponsored by: